Nitroglycerin-transdermal - Novosis Pharma AG

Drug Profile

Nitroglycerin-transdermal - Novosis Pharma AG

Latest Information Update: 21 Jul 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novosis Pharma
  • Class
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Angina pectoris

Most Recent Events

  • 21 Jul 2004 No development reported - Preclinical for Angina pectoris in Germany (Transdermal)
  • 21 Nov 2001 New profile
  • 21 Nov 2001 Preclinical development for Angina pectoris in Germany (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top